DIVA Laboratories Ltd (4153) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of DIVA Laboratories Ltd stock TWD 21.82, price TWD 30.95, that is 29.5% below the price, quality 67 out of 100. Rating: overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range 20.76 TWD – 55.44 TWD · fair‑value band 16.68 TWD – 26.94 TWD · the 30.95 TWD price screens above the 21.82 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow DIVA Laboratories in your weekly email
Every Wednesday you see whether DIVA Laboratories is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
DIVA Laboratories, Ltd. engages in the research, development, manufacture, and sale of medical devices and computer peripherals worldwide.
Show moreShow less
The company provides endo/surgical displays for hybrid and other types of OR applications; color and mono displays for radiology applications; and touch and embedded display, as well as industrial displays. DIVA Laboratories, Ltd. was founded in 1984 and is headquartered in New Taipei City, Taiwan.
Stock analysis
DIVA Laboratories Ltd (4153) currently trades at 30.95 TWD, while our model-based Fair Value estimate is 21.82 TWD, 29% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 34.19 TWD per share, and 4 of the 24 models we run sit above the 30.95 TWD price.
Bear case: the Asset-Based group reads lowest at 12.95 TWD, and 20 of the 24 models stay below the price. Data coverage for this calculation is low.
Scenario range: 16.68 TWD (bear) to 26.94 TWD (bull), the price of 30.95 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 67/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
DIVA Laboratories Ltd reported revenue of 869M TWD in FY2025 versus 712M TWD in FY2021, a compound +5.1%/yr. Reported net income was 90.5M TWD in FY2025, compounding +42.7%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.
Key figures
Market cap 1.8B TWD (≈ $55.3M) Micro · P/E ratio 19.0 · P/S ratio 1.92 · EPS (TTM) 1.63 TWD · Dividend yield 6.5% · Net margin 12.2% · Return on equity 11.5% · Return on assets (EBIT) 7.1% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 54 out of 100 (low confidence).
What moves the price
The share trades about 14% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at −29%, 4153 screens richer than that median.
Fair Value models
Bear16.68 TWDFair Value 21.82 TWDBull26.94 TWD
Price 30.95 TWD · Downside -29.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+0.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.3%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.2%
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+39.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+32.9%
Dividend (yield on the price)6.5%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.8% → 13%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+41.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +39.0% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks
Beats the industry median on 12/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score67 · Top 25%
Fair Value upside−29.5% · Above median
Profitability
Return on equity (12 months)11.5% · Above median
Return on assets6.7% · Top 25%
Net margin (12 months)12.2% · Above median
Operating margin (12 months)15.0% · Above median
Growth and dividend
Revenue growth (quarter YoY)26.1% · Top 25%
Dividend yield (12 months)6.5% · Top 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is DIVA Laboratories Ltd (4153) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 21.82 TWD versus a price of 30.95 TWD, about 29% lower (overvalued).
What is the fair value of 4153?
Our model-based fair value for DIVA Laboratories Ltd is 21.82 TWD (as of Nov 9, 2026), built from audited fundamentals. The current price: 30.95 TWD.
What is the quality score of 4153?
DIVA Laboratories Ltd has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DIVA Laboratories Ltd (4153)?
Our model-based price target is the fair value of 21.82 TWD (as of Nov 9, 2026) from 24 valuation models. Cautious scenario 16.68 TWD, optimistic scenario 26.94 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the DIVA Laboratories Ltd stock forecast for 2026?
Our models put fair value at 21.82 TWD, about 29% lower versus a price of 30.95 TWD (overvalued). Cautious scenario 16.68 TWD, optimistic scenario 26.94 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of DIVA Laboratories Ltd (4153)?
DIVA Laboratories Ltd reported trailing-twelve-month revenue of about 946M TWD (latest available figure, as of Nov 9, 2026).
Does DIVA Laboratories Ltd pay a dividend?
DIVA Laboratories Ltd currently shows a dividend yield of 6.46% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of DIVA Laboratories Ltd (4153) and when is the ex-dividend date?
DIVA Laboratories Ltd pays a dividend of 2.00 TWD per share a year, a dividend yield of 6.5%. The last ex-dividend date was Jun 12, 2026. A dividend has been paid every year since 2019. The payout ratio is 123% of earnings. Free cash flow covers the dividend 0.17 times. Our assessment: Pays more than it earns. The company pays out more in dividends than it earns, and free cash flow clearly does not cover the dividend either. It may need to be cut unless profits recover.
What growth is priced into DIVA Laboratories Ltd (4153)?
For today's price to be fair in a discounted-cash-flow model, DIVA Laboratories Ltd would have to grow free cash flow by +41.2 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +3.4 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of 4153 use?
Our models discount DIVA Laboratories Ltd at 11.8 %: a base by market capitalisation (micro), damped by beta 0.26, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For DIVA Laboratories Ltd that is +41.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has DIVA Laboratories Ltd (4153) delivered so far?
Over the past 5 years revenue at DIVA Laboratories Ltd grew +3.4 % a year. The price currently implies free-cash-flow growth of +41.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of DIVA Laboratories Ltd (4153) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into DIVA Laboratories Ltd (+41.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of DIVA Laboratories Ltd (4153)?
The free-cash-flow yield on the price is 1.09 %: that much free cash flow DIVA Laboratories Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of DIVA Laboratories Ltd (4153)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DIVA Laboratories Ltd it is 21.82 TWD per share (as of Nov 9, 2026), against a price of 30.95 TWD. It is the blended result of 24 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is DIVA Laboratories Ltd stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 4153 trades above its calculated fair value: price 30.95 TWD, fair value 21.82 TWD, a gap of about −29% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4153?
No. The price is what the market pays today (30.95 TWD); the fair value is what the company's own numbers justify (21.82 TWD). For DIVA Laboratories Ltd the two are 9.13 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is DIVA Laboratories Ltd worth?
The market values DIVA Laboratories Ltd at about 1.8B TWD (market capitalisation, as of Nov 9, 2026). Per share that is 30.95 TWD; our models calculate a fair value of 21.82 TWD per share.
What do the bullish and bearish scenarios say about 4153?
Our models span a range for DIVA Laboratories Ltd: cautious scenario 16.68 TWD, base 21.82 TWD, optimistic 26.94 TWD per share (as of Nov 9, 2026, price 30.95 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4153?
DIVA Laboratories Ltd trades at a price-to-earnings ratio of 19.0 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 21.82 TWD is built from several models across several years. Median P/E at fiscal year-end, 6 fiscal years (2020 to 2025), reported earnings: 38.7. Other multiples: P/B 1.8, P/S 1.9, EV/EBITDA 9.8.
How solid is the balance sheet of DIVA Laboratories Ltd (4153)?
Balance-sheet figures for DIVA Laboratories Ltd (as of Nov 9, 2026): return on equity 11.5%. They feed the Quality Score of 67/100, which measures business quality independently of the share price.
How far is 4153 from its 52-week high?
DIVA Laboratories Ltd trades at 30.95 TWD, about 14% below its 52-week high of 35.90 TWD and 4% above the low of 29.69 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 21.82 TWD is for.
Which stocks are comparable to DIVA Laboratories Ltd?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DIVA Laboratories Ltd stock attractive at the current price?
The data as of Nov 9, 2026: price 30.95 TWD, calculated fair value 21.82 TWD (−29%), Quality Score 67/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4153 calculated?
We run DIVA Laboratories Ltd through 24 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 21.82 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. DIVA Laboratories Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DIVA Laboratories Ltd (4153)?
The closing price on Nov 9, 2026 was 30.95 TWD. Our model-based fair value is 21.82 TWD, about 29% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DIVA Laboratories Ltd right now?
The price sits above even our optimistic bull case (26.94 TWD). The favourable scenario is already priced in. Solid but not exceptional quality (67/100) and above fair value, neither a clear bargain nor a standout compounder. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of DIVA Laboratories Ltd
How large is the market capitalisation of DIVA Laboratories Ltd (4153)?
The market capitalisation of DIVA Laboratories Ltd is 1.8B TWD (≈ $55.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of DIVA Laboratories Ltd (4153)?
The price-to-sales ratio of DIVA Laboratories Ltd is 1.92 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of DIVA Laboratories Ltd (4153)?
Earnings per share at DIVA Laboratories Ltd are 1.63 TWD (price ÷ EPS = P/E 19.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of DIVA Laboratories Ltd (4153)?
The dividend yield of DIVA Laboratories Ltd is 6.5% (payout 123%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of DIVA Laboratories Ltd (4153)?
The net margin of DIVA Laboratories Ltd is 12.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of DIVA Laboratories Ltd (4153)?
The return on equity (ROE) of DIVA Laboratories Ltd is 11.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of DIVA Laboratories Ltd (4153)?
On an EBIT basis the return on assets of DIVA Laboratories Ltd is 7.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of DIVA Laboratories Ltd (4153)?
The operating margin of DIVA Laboratories Ltd is 15.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at DIVA Laboratories Ltd (4153)?
Revenue at DIVA Laboratories Ltd is growing +26.1% versus a year earlier (3y avg −2.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at DIVA Laboratories Ltd (4153)?
Earnings per share at DIVA Laboratories Ltd are growing +188% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does DIVA Laboratories Ltd (4153) hold?
DIVA Laboratories Ltd holds more cash than debt, 346M TWD net (fiscal year 2022). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch DIVA Laboratories Ltd in the live analysis
One click puts DIVA Laboratories Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 9, 2026